Objective. The aim of the study was to evaluate the rates of adverse events in patients exposed to different regimens of antiviral treatment for HCV infection.

Materials and methods. The study was conducted in Minsk City Center for Infectious Hepatology (Minsk City Clinical Hospital for Infectious Diseases). Totally, the study included 755 patients. To analyze development of undesirable effects under the antiviral treatment all patients were divided into 4 groups depending on the drug therapy regimen used.

Results. Adverse events were observed in every group comprising totally 51.39% (388/755). Among the patients treated with interferon and ribavirin, the rate of adverse events was 95.8% (137/143). In the patients received ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin and either sofosbuvir/ledipasvir ± ribavirin or sofosbuvir+daclatasvir ± ribavirin, adverse events rates were registered in 50.0% (16/32) and 39.65% (226/570), respectively.

Conclusion. After direct-acting antivirals were introduced in the treatment for HCV, the rates of anemia, thrombocytopenia, and leucopenia decreased significantly. The anemia incidence during the treatment with direct-acting antivirals could be attributed to ribavirin administration. The highest anemia incidence rates were observed during the first month of the treatment with direct-acting antivirals. Though adverse events during the direct-acting antivirals administration are not rare, their intensity was modest.